Long‐term outcome of patients with acquired chronic pure red cell aplasia (<scp>PRCA</scp>) following immunosuppressive therapy: a final report of the nationwide cohort study in 2004/2006 by the Japan <scp>PRCA</scp> collaborative study group

  • Makoto Hirokawa
    Department of General Internal Medicine and Clinical Laboratory Medicine Akita University Graduate School of Medicine Akita Japan
  • Kenichi Sawada
    Department of Haematology, Nephrology and Rheumatology Akita University Graduate School of Medicine Akita Japan
  • Naohito Fujishima
    Department of Haematology, Nephrology and Rheumatology Akita University Graduate School of Medicine Akita Japan
  • Masanao Teramura
    Department of Haematology Tokyo Women's Medical University Tokyo Japan
  • Masami Bessho
    Haematology Division Department of Internal Medicine Saitama Medical University Saitama Japan
  • Kazuo Dan
    Department of Haematology Nippon Medical School Tokyo Japan
  • Hisashi Tsurumi
    First Department of Internal Medicine Gifu University School of Medicine Gifu Japan
  • Shinji Nakao
    Department of Cellular Transplantation Biology Kanazawa University Graduate School of Medicine Kanazawa Japan
  • Akio Urabe
    Division of Haematology NTT Medical Centre Tokyo Japan
  • Shin Fujisawa
    Department of Haematology Yokohama City University Medical Centre Yokohama Kanagawa Japan
  • Yuji Yonemura
    Department of Transfusion Medicine and Cell Therapy Blood Transfusion Service Kumamoto University School of Medicine Kumamoto Japan
  • Fumio Kawano
    National Hospital Organization Kumamoto National Hospital Medical Centre Kumamoto Japan
  • Kazuo Oshimi
    Division of Haematology Juntendo University School of Medicine Tokyo Japan
  • Koichi Sugimoto
    Division of Haematology Juntendo University School of Medicine Tokyo Japan
  • Akira Matsuda
    Saitama International Medical Centre Saitama Medical University Saitama Japan
  • Masamitsu Karasawa
    Blood Transfusion Service Gunma University Hospital Maebashi Gunma Japan
  • Ayako Arai
    Department of Haematology Tokyo Medical and Dental University Tokyo Japan
  • Norio Komatsu
    Division of Haematology Juntendo University School of Medicine Tokyo Japan
  • Hideo Harigae
    Department of Haematology and Immunology Tohoku University Graduate School of Medicine Sendai Japan
  • Mitsuhiro Omine
    Division of Haematology, Internal Medicine Showa University Fujigaoka Hospital Yokohama Japan
  • Keiya Ozawa
    Division of Haematology Department of Medicine Jichi Medical School Tochigi Japan
  • Mineo Kurokawa
    Department of Haematology and Oncology Graduate School of Medicine The University of Tokyo Tokyo Japan

説明

<jats:title>Summary</jats:title><jats:p>Immunosuppressive therapy has been employed as the initial treatment for acquired chronic pure red cell aplasia (<jats:styled-content style="fixed-case">PRCA</jats:styled-content>), such as idiopathic, thymoma‐associated, or large granular lymphocyte (<jats:styled-content style="fixed-case">LGL</jats:styled-content>) leukaemia‐associated <jats:styled-content style="fixed-case">PRCA</jats:styled-content>, which is thought to be immune‐mediated. To explore the overall long‐term outcome following immunosuppression and to identify the risk factors for death in these disorders, we conducted nationwide surveys in Japan 2004 and 2006, and identified a total of 185 patients with acquired chronic <jats:styled-content style="fixed-case">PRCA</jats:styled-content>, including 72 idiopathic, 41 thymoma‐associated and 14 <jats:styled-content style="fixed-case">LGL</jats:styled-content> leukaemia‐associated cases of <jats:styled-content style="fixed-case">PRCA</jats:styled-content> for whom data was available. The present study evaluated 127 patients with these three subsets of <jats:styled-content style="fixed-case">PRCA</jats:styled-content>. The median overall survival has not yet been reached in idiopathic <jats:styled-content style="fixed-case">PRCA</jats:styled-content>. The estimated median overall survival times in patients with thymoma‐associated and <jats:styled-content style="fixed-case">LGL</jats:styled-content> leukaemia‐associated <jats:styled-content style="fixed-case">PRCA</jats:styled-content> were 142·1 and 147·8 months, respectively. Twenty‐two deaths were reported, and the response to induction therapy and relapse of anaemia were found to be associated with death. The major causes of death were infection in seven patients and organ failure in another seven patients. The results suggest that maintenance therapy and the management of infectious complications are crucial for improving the prognosis of chronic <jats:styled-content style="fixed-case">PRCA</jats:styled-content>.</jats:p>

収録刊行物

被引用文献 (7)*注記

もっと見る

参考文献 (27)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ